Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Registered Reporters Are Invited to Three Virtual MSVirtual2020 Press Conferences Featuring: The Latest Clinical Study Outcomes, Advances in Therapeutics, Diagnostics and Technologies, and Late Breakers and COVID-19 Impact on MS Research & Patient Care

Newswise — The 8th Joint ACTRIMS-ECTRIMS meeting – the largest international conference focused on research in multiple sclerosis (MS), will be held in a virtual format from September 11-13, 2020, with a special encore session featuring Late-Breaking News and a COVID-19 Session on September 26.   At this virtual conference – MSVirtual2020 – highly regarded scientists, neurologists, clinicians and researchers from around the world will be presenting the latest research, clinical trial outcomes and diagnostic advances in multiple sclerosis (MS). Registered reporters will have access to the full program and press events. 

MSVirtual2020 will have a Newsroom that will house material that media can use such as bios of leaders and key speakers, MS infographics, MSVirtual2020 press releases, videos of ACTRIMS and ECTRIMS leaders, late breaker investigator summary videos (Available September 21  for media-only, under embargo), and other materials that may be of interest.  This Newsroom can be found at: https://www.newswise.com/home/actrims

Additionally, this Newsroom site will host three live press events for media-only. These events are designed to provide reporters with opportunities to hear from leaders and experts directly, ask them questions on the presentations being featured at the conference, hear clinical outcomes and breakthroughs (as well as some of the key advances being made in treatment, diagnostics and technologies as well as rehabilitation). There will also be a special press event focused on the late breakers and the Impact of COVID-19 on MS. The abstracts for this event will be available upon request to the press manager on September 21st.   The sessions will have a live Q&A session where media will be able to ask questions directly to the late breaker investigators and the COVID-19 presenters.   

Link to Press Events: 

PRESS EVENTS

Opening Press Conference with ACTRIMS and ECTRIMS Leaders with live Q&A (Media only)

    • Date: Friday, September 11th @8:00 a.m. ET 
    • Focus:  Key Highlights of Conference by ACTRIMS and ECTRIMS leaders 
    • Featured Speakers:  
      • Jeffrey Cohen, MD, President of ACTRIMS, Director of Mellen Center for Multiple Sclerosis Doctors, Cleveland Clinic
      • Bernhard Hemmer, PhD, President of ECTRIMS and Director of the Neurology Clinic Technical University of Munich (TUM), 
      • Benjamin Segal, MD, Scientific Program Committee Co-Chair of MSVirtual2020 and chair of the Department of Neurology and Director of the Neurological Research Institute at The Ohio State University College of Medicine, 
      • Maria Pia Amato, MD, Scientific Program Committee Co-Chair of MSVirtual2020, and Associate Professor of Neurology and head of MS Unit at the Department of Neurology, University of Florence
    • Link to Press Event:  https://newswiselive.zoom.us/j/7459578068
  • Virtual Coffee Break with ACTRIMS & ECTRIMS Presidents with an interactive Q&A (Media Only)
    • Date: Sunday, September 13th @ 7:30 a.m. ET
    • Focus: A Q&A session where media will have the opportunity to ask the Presidents questions regarding key conference presentations, clinical trial outcomes, advances in therapeutic research, technology and rehabilitation, and garner commentary from them. 
    • Featured Leaders:
      • Jeffrey Cohen, MD, President of ACTRIMS, and Director of Mellen Center for Multiple Sclerosis Doctors, Cleveland Clinic
      • Bernhard Hemmer, PhD, President of ECTRIMS and Director of the Neurology Clinic Technical University of Munich (TUM), 

Upcoming as part of the MSVirtual2020 Encore session:

  • Late-Breaker and COVID-19 Press Event – Live Q&A with Investigators (Media only)
    • Date: Friday, September 25th @ 9:00 a.m.ET
    • Focus: Live Q&A with Late Breaker and special COVID-19  Investigators
    • Abstracts Available Under embargo as of September 21 upon request to press manager: lynn.blenkhorn@ogilvy.com
    • Featured Speakers:  Late Breaker Investigators and COVID-19 Presenters
    • Link to Press Event: https://newswiselive.zoom.us/j/7459578068




Filters close

Showing results

110 of 3699
Released: 19-Oct-2020 4:20 PM EDT
Patients Who Had More Severe Covid-19 May Be the Best Donors for Convalescent Plasma Therapy
Johns Hopkins Bloomberg School of Public Health

Sex, age, and severity of disease may be useful in identifying COVID-19 survivors who are likely to have high levels of antibodies that can protect against the disease.

access_time Embargo lifts in 2 days
Embargo will expire: 20-Oct-2020 10:00 AM EDT Released to reporters: 19-Oct-2020 4:05 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 20-Oct-2020 10:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 19-Oct-2020 3:05 PM EDT
Experts haven’t changed their estimates for COVID-19 immunity duration, despite Trump's claim
Newswise

We rate this claim as mostly false. Infectious disease experts did not shift from saying immunity was lifelong to saying it lasted only a few months for partisan reasons. Experts haven’t changed their estimates for immunity duration, which remains unknown. Most agree that it is not a "life-time".

Newswise: 246157_web.jpg
Released: 19-Oct-2020 1:50 PM EDT
CBD helps reduce lung damage from COVID by increasing levels of protective peptide
Medical College of Georgia at Augusta University

One way CBD appears to reduce the "cytokine storm" that damages the lungs and kills many patients with COVID-19 is by enabling an increase in levels of a natural peptide called apelin, which is known to reduce inflammation and whose levels are dramatically reduced in the face of this storm.

Released: 19-Oct-2020 1:35 PM EDT
Fear of COVID-19 raises risk of depression among Soweto's deprived communities
Cambridge University Press

A STUDY into the impact of the COVID-19 lockdown on the mental health of people in Soweto has found a significant link between symptoms of depression and how likely people felt they were to be infected.

Released: 19-Oct-2020 1:25 PM EDT
Coronavirus Test Results Are Faster but Still Too Slow For Contract Tracing, National Survey Says
Rutgers University-New Brunswick

The average test times for coronavirus results have fallen from four days in April to 2.7 days in September, but results are still too slow for effective contact tracing, according to a new nationwide survey led by researchers from Rutgers University–New Brunswick and Northeastern, Harvard and Northwestern universities.

Newswise: 246236_web.jpg
Released: 19-Oct-2020 1:15 PM EDT
Researchers investigate impact of COVID-19 on BAME businesses
Staffordshire University

Black, Asian and Minority Ethnic (BAME) businesses have had to incur considerable costs to protect their businesses through lockdown, according to academics at Staffordshire University.

Released: 19-Oct-2020 1:05 PM EDT
Criteria to predict cytokine storm in COVID-19 patients identified by Temple Researchers
Temple University Health System

Like a cold front that moves in, setting the stage for severe weather, coronavirus infection triggers showers of infection-fighting immune molecules - showers that sometimes escalate into a chaotic immune response known as a cytokine storm.

Newswise: 246249_web.jpg
Released: 19-Oct-2020 12:55 PM EDT
COVID-19 pandemic has dramatic impact on osteoporosis management, finds new global study
International Osteoporosis Foundation

A new study published prior to World Osteoporosis Day finds that the COVID-19 pandemic, which has severely affected management of non-communicable diseases, is markedly impacting the management of osteoporosis as judged by access to online FRAX fracture risk assessments.


Showing results

110 of 3699

close
1.06293